Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614939 | 0.80 | IDO1 (0.51) | CYP11B2CYP11B1PIM1IDO1PIM3 | |
| SCHEMBL10165308 | 0.79 | CYP11B2 (0.55) | CYP11B2CYP11B1IDO1TDO2 | |
| SCHEMBL18850044 | 0.79 | CYP11B1 (0.50) | CYP11B2CYP11B1LMNA | |
| SCHEMBL17463142 | 0.79 | CYP11B1 (0.46) | CYP11B2CYP11B1IDO1LMNA | |
| SCHEMBL5646784 | 0.79 | KIF11 (0.47) | CYP11B2CYP11B1KIF11PIM1PARP1 | |
| SCHEMBL21682820 | 0.79 | PIM1 (0.61) | CYP11B2CYP11B1KIF11PIM1PARP1 | |
| SCHEMBL4439117 | 0.79 | CYP11B2 (0.60) | CYP11B2CYP11B1KIF11PIM1PARP1 | |
| SCHEMBL2609389 | 0.78 | KIF11 (0.43) | CYP11B2CYP11B1KIF11PIM1IDO1 | |
| SCHEMBL2615265 | 0.76 | CCR1 (0.54) | KIF11 | |
| SCHEMBL23602043 | 0.76 | SIGMAR1 (0.43) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379535-B1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | CYP11B2 172/4885CYP11B1 189/4885KIF11 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.